CTMX Stock Analysis: CytomX Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 829m USD | 12M Return: 62% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.0M
Qual. Beats: 0
Rev. Trend: -27.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CytomX Therapeutics is a clinical-stage oncology biopharmaceutical company developing conditionally activated biologics designed to be activated preferentially within the tumor microenvironment, aiming to widen the therapeutic window for potent cancer therapies. Its pipeline includes T-cell engagers such as CX-904 (targeting EGFR and CD3), conditionally activated ADCs like CX-2051 (EpCAM) and CX-2029 (CD71), and the masked cytokine CX-801 (interferon alpha-2b PROBODY), alongside the partnered program BMS-986288, a PROBODY version of ipilimumab.
The companys lead technology platforms are its conditional activation approach and the PROBODY platform, which rely on masking antibodies or other biologics so they remain largely inert in healthy tissue and become preferentially unmasked by tumor-associated proteases. This design is intended to reduce systemic toxicity, a key limitation of many conventional ADCs and T-cell engagers, and to enable targeting of antigens that are otherwise difficult to drug due to expression in normal tissues.
CytomX works through a partnership-heavy business model, with strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, plus a clinical supply agreement with Merck to evaluate CX-801 in combination with KEYTRUDA (pembrolizumab). Founded in 2008 and headquartered in South San Francisco, California-a major cluster for U.S. biotech innovation-the company is classified within the Health Care sectors Biotechnology sub-industry and trades on NASDAQ under the ticker CTMX.
- CX-904 EGFR T-cell engager Phase 1 data catalyst
- Partnership milestone payments from Astellas Amgen Regeneron
- Cash runway narrows as R&D burn accelerates
| Net Income: -59.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 60.47 > 1.0 |
| NWC/Revenue: 897.7% < 20% (prev 24.69%; Δ 873.0% < -1%) |
| CFO/TA -0.22 > 3% & CFO -80.1m > Net Income -59.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.3m) vs 12m ago 103.4% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 15.53% > 50% (prev 149.8%; Δ -134.3% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 353.1m - Total Current Liabilities 34.0m) / Total Assets 359.4m |
| B: -2.03 (Retained Earnings -730.2m / Total Assets 359.4m) |
| C: -0.26 (EBIT TTM -58.9m / Avg Total Assets 228.9m) |
| D: 8.12 (Book Value of Equity 319.9m / Total Liabilities 39.4m) |
| Altman-Z'' = 5.99 = AAA |
| DSRI: 1.37 (Receivables 646k/1.96m, Revenue 35.5m/147.6m) |
| GMI: 1.00 (GM 98.80% / 99.29%) |
| AQI: 0.31 (AQ_t 0.01 / AQ_t-1 0.03) |
| SGI: 0.24 (Revenue 35.5m / 147.6m) |
| TATA: 0.06 (NI -59.1m - CFO -80.1m) / TA 359.4m) |
| Beneish M = -3.67 (Cap -4..+1) = AAA |
As of July 08, 2026, the stock is trading at USD 3.84 with a total of 3,193,213 shares traded. Over the past week, the price has changed by +2.67%, over one month by +30.61%, over three months by -10.70% and over the past year by +62.03%.
Current recommended Stop Loss: 3.30 (which is 14.1% or 2.5 ATR below the current price).
CytomX Therapeutics has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy CTMX.
- StrongBuy: 2
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.5 | 225.5% |
P/E Forward = 14.2045
P/S = 23.3371
P/B = 2.5993
P/EG = -1.8
Revenue TTM = 35.5m USD
EBIT TTM = -58.9m USD
EBITDA TTM = -57.7m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 2.86m USD (from shortTermDebt, last quarter)
Debt = 2.86m USD (from shortLongTermDebtTotal, last quarter) (leases 2.86m already included)
Net Debt = -343.9m USD (calculated: Debt 2.86m - CCE 346.7m)
Enterprise Value = 485.6m USD (829.4m + Debt 2.86m - CCE 346.7m)
Interest Coverage Ratio = unknown (Ebit TTM -58.9m / Interest Expense TTM 0.0)
EV/FCF = -6.06x (Enterprise Value 485.6m / FCF TTM -80.2m)
FCF Yield = -16.51% (FCF TTM -80.2m / Enterprise Value 485.6m)
FCF Margin = -225.6% (FCF TTM -80.2m / Revenue TTM 35.5m)
Net Margin = -166.4% (Net Income TTM -59.1m / Revenue TTM 35.5m)
Gross Margin = unknown ((Revenue TTM 35.5m - Cost of Revenue TTM 251k) / Revenue TTM)
Tobins Q-Ratio = 1.35 (Enterprise Value 485.6m / Total Assets 359.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.86m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -46.5m (EBIT -58.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.38 (Total Current Assets 353.1m / Total Current Liabilities 34.0m)
Debt / Equity = 0.01 (Debt 2.86m / totalStockholderEquity, last quarter 319.9m)
Debt / EBITDA = 5.96 (negative EBITDA) (Net Debt -343.9m / EBITDA -57.7m)
Debt / FCF = 4.29 (negative FCF - burning cash) (Net Debt -343.9m / FCF TTM -80.2m)
Total Stockholder Equity = 161.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.83% (Net Income -59.1m / Total Assets 359.4m)
RoE = -36.61% (Net Income TTM -59.1m / Total Stockholder Equity 161.6m)
RoCE = -36.46% (EBIT -58.9m / Capital Employed (Equity 161.6m + L.T.Debt 0.0))
RoIC = -14.26% (negative operating profit) (NOPAT -46.5m / Invested Capital 326.4m)
WACC = 17.18% (E(829.4m)/V(832.3m) * Re(17.24%) + D(2.86m)/V(832.3m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 17.24% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 86.67 | Cagr: 53.79%
[DCF] Fair Price = unknown (Cash Flow -80.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: -27.03 | Revenue CAGR: -11.14% | SUE: 0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=+1.27% | Revisions=-22% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=+4.54% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.42 | Chg30d=+2.95% | Revisions=-22% | GrowthEPS=-180.6% | GrowthRev=-53.1%
EPS next Year (2027-12-31): EPS=-0.49 | Chg30d=+2.12% | Revisions=+0% | GrowthEPS=-15.4% | GrowthRev=-4.2%
[Analyst] Revisions Ratio: -15% (up=10, down=14)